最新ニュース e.l.f. Beauty (NYSE:ELF) 株価情報

e.l.f. Beauty

e.l.f. Beauty Inc is a multi-brand beauty company that offers inclusive, accessible, clean, vegan and cruelty-free cosmetics and skin care products. The Company's mission is to make the best of beauty accessible to every eye, lip, face, and skin concern. The company offers cosmetic accessories for women which include eyeliner, mascara, false eyelashes, lipstick, the foundation for the face, moisturizer, cleanser, and other tools through its stores and e-commerce channels. The products that the company sells are marketed under the e.l.f. Cosmetics, W3LL PEOPLE and Keys Soulcare brands. It carries out sales within the US and internationally, out of which maximum revenue is generated from the US.

News

Movers

BBWI

BLDR

DELL

FWONA

NICE

過去1週間でこれらの10つの大型株は最も悪いパフォーマンスを発揮しました。それで、あなたのポートフォリオに含まれていますか？

大型株パフォーマンス下落　NIOを筆頭に

e.l.f. Beauty Inc

aelf

E-L Financial Corp Ltd

ALPS Electrification Infrastructure ETF

Scotiabank initiates coverage on CG Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGON#NASDAQ">CGON</a>) with a Sector Perform rating and announces Price Target of $23.

Price Target

Initiation

Analyst Ratings

CGON

Scotiabank Initiates Coverage On CG Oncology with Sector Perform Rating, Announces Price Target of $23

SOBO

South Bow Safely Restarted The Keystone Pipeline After Receiving Regulatory Approval From The Pipeline And Hazardous Materials Safety Administration, Following South Bow's Response To An Oil Release At Milepost 171 Of Keystone On April 8, 2025, Near Fort Ransom, North Dakota

BCTX

BriaCell Therapeutics Announces New Positive Survival Data In Its Phase 2 Study Of Bria-IMT Plus Check Point Inhibitors (CPI), Outperforming ADC Drugs In Hormone Receptor Positive (HR+) Metastatic Breast Cancer (MBC) Patients

President Donald Trump ordered a probe into tariffs on critical mineral imports, <a href="https://www.benzinga.com/markets/commodities" target="_blank" rel="noreferrer noopener">commodities</a> that are essential for the defense, energy, and technology sectors.
What happened? On Tuesday, Trump <a target="_blank" href="https://www.whitehouse.gov/presidential-actions/2025/04/ensuring-national-security-and-economic-resilience-through-section-232-actions-on-processed-critical-minerals-and-derivative-products/" rel="noreferrer noopener">signed an executive order</a> directing Commerce Secretary Howard Lutnick to conduct a national security review under Section 232 of the Trade Expansion Act—the same authority previously used to impose tariffs on steel and aluminum. Lutnick has 180 days to report back with findings, including recommendations on whether and how tariffs should be applied.
The probe will assess vulnerabilities in the supply chains of 50 minerals, including all the steps, from raw extraction to producing semi-finished goods like battery cathodes and wind turbines. The list will include rare earth elements and metals like cobalt, nickel, lithium, and uranium.
This order follows China's April 4 move to impose export controls on seven rare earth elements, which has effectively halted global shipments, as China currently supplies 30 of the 50 critical minerals listed by the U.S. Geological Survey.
Why It Matters? The U.S. reliance on imported critical minerals, particularly from geopolitical rivals like China, poses serious security and economic stability risks. These minerals are essential for advanced military systems, electric vehicles, renewable energy infrastructure, and consumer electronics.
Critical minerals experts Gracelin Baskaran and Meredith Schwartz from the Center for Strategic and International Studies warned about the lack of alternative supply chains.
"The restrictions apply to seven medium and heavy rare earths: samarium, gadolinium, terbium, dysprosium, lutetium, scandium, and yttrium. The United States is particularly vulnerable to these supply chains. Until 2023, China accounted for 99 percent of global heavy REEs processing," they <a target="_blank" href="https://www.csis.org/analysis/consequences-chinas-new-rare-earths-export-restrictions" rel="noreferrer noopener">said</a> in a discussion.
Baskaran and Schwartz noted that these minerals are foundational to advanced military systems, yet the U.S. has no capacity for heavy rare earth separation today.
Trump might find the solution on the seabed floor. His administration is reportedly drafting an executive order to fast-track seabed mining, and potato-sized nodules on the ocean floor contain vast amounts of cobalt, nickel, and rare earths.
"As the Trump administration has done with shipbuilding and critical minerals more broadly, catalyzing US government focus on the areas of greatest vulnerability to PRC (China) ambitions is essential," Alexander Gray, chief of staff to the U.S. national security adviser in the first Trump administration, <a target="_blank" href="https://www.ft.com/content/2205fc9a-67b5-4112-9b7f-cd89d011f5bb" rel="noreferrer noopener">said</a> for The Financial Times.
The U.S. has been absent from international negotiations on seabed mining as the International Seabed Authority's March conference ended without a go-ahead for mining in international waters, as environmentalists argued a poorly understood impact on the ecosystem.
Meanwhile, Vancouver-based The Metals Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMC#NASDAQ">TMC</a>) has confirmed that its subsidiary <a target="_blank" href="https://www.benzinga.com/government/regulations/25/03/44543787/tmc-pushes-for-the-fastest-pathway-to-commercial-production-despite-environmental-risks" rel="noreferrer noopener">initiated the permitting process</a> for exploring and mining international waters under a 1980 U.S. law. Still, debates persist about whether the U.S. can grant rights over something outside its jurisdiction.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/economics/macro-economic-events/25/04/44795047/exclusive-tariff-uncertainty-turns-traders-cautious-but-oil-silver-might-be-the-escape-hatch-says-market-analyst" target="_blank" rel="noreferrer noopener">Tariff Uncertainty Turns Traders Cautious — But Oil, Silver Might Be The Escape Hatch, Says Market Analyst</a></li>
</ul>
Image via Shutterstock

Government

Regulations

Commodities

Politics

Markets

Media

Trump Orders Critical Minerals Probe As China Tightens Controls Over Rare Commodities In Retaliatory Move

BLUE

Carlyle, SK Capital Partners, And Beacon Parent Holdings Announced That Beacon Merger Sub, Inc. Has Extended The Expiration Date Of Its Offer To Acquire All Of The Outstanding Common Stock Of Bluebird Bio, To Expire At One Minute After 11:59 P.M., New York City Time, On May 2, 2025

HC Wainwright &amp; Co. analyst Emily Bodnar maintains TransCode Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNAZ#NASDAQ">RNAZ</a>) with a Buy and lowers the price target from $20 to $10.

RNAZ

HC Wainwright & Co. Maintains Buy on TransCode Therapeutics, Lowers Price Target to $10

Scotiabank analyst Allan Verkhovski initiates coverage on Paylocity Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCTY#NASDAQ">PCTY</a>) with a Sector Perform rating and announces Price Target of $190.

PCTY

Scotiabank Initiates Coverage On Paylocity Holding with Sector Perform Rating, Announces Price Target of $190

Silvercorp Metals (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/SVM#AMEX">SVM</a>) reported quarterly sales of $75.10 million which beat the analyst consensus estimate of $58.30 million by 28.82 percent. This is a 75.96 percent increase over sales of $42.68 million the same period last year.

Earnings

Earnings Beats

Silvercorp Metals Q4 Sales $75.10M Beat $58.30M Estimate

WIIM

BriaCell Therapeutics shares are trading higher after the company announced new survival data from its Phase 2 study of Bria-IMT plus check point inhibitors.

JP Morgan analyst Bill Peterson downgrades United States Steel (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/X#NYSE">X</a>) from Overweight to Neutral and lowers the price target from $43 to $38.

Downgrades

JP Morgan Downgrades United States Steel to Neutral, Lowers Price Target to $38

HC Wainwright &amp; Co. analyst Mitchell Kapoor reiterates Legend Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LEGN#NASDAQ">LEGN</a>) with a Buy and maintains $75 price target.

Reiteration

LEGN

HC Wainwright & Co. Reiterates Buy on Legend Biotech, Maintains $75 Price Target

Biotech

General

BriaCell Therapeutics Announces New Survival Data In Phase 2 Study Of Bria-IMT Plus Check Point Inhibitors; Says 'Median Overall Survival Of 17.3 Months Exceeds Historical Data Of 14.4 Months In TRODELVY, Says 'Survival data in triple negative breast cancer patients treated with the BriaCell regimen was comparable to TRODELVY'

LVTX

LAVA Therapeutics Announced That The Netherlands Enterprise Agency (Rijksdienst Voor Ondernemend Nederland, Rvo) Granted A Full Waiver Of The Final Payment Obligation Related To The Innovation Credit, In The Amount Of $5.1M

ABBOTT'S FINANCIAL GUIDANCE Abbott projects full-year 2025 organic sales growth to be in the range of 7.5% to 8.5%.
Abbott projects full-year 2025 adjusted operating margin to be 23.5% to 24.0% of sales.
Abbott projects full-year 2025 adjusted diluted earnings per share of $5.05 to $5.25 and second-quarter 2025 adjusted diluted earnings per share of $1.23 to $1.27.

Large Cap

Guidance

Health Care

Abbott Reaffirms 2025 Adjusted EPS Of $5.05-$5.25 And Consensus Of $5.15, With Organic Sales Growth Of 7.5%-8.5% And Adjusted Operating Margin Of 23.5%-24.0%

LYFT

Lyft Announced It Has Entered Into A Definitive Agreement To Acquire Freenow From BMW Group And Mercedes-benz Mobility For Approximately €175M Or $197M In Cash

Designed to assess the impact of CardiolRx&#x2122; on preventing episodes of recurrent pericarditis, the first patient has been randomized by Northwestern University in Chicago.
Based on a successful end-of-Phase II meeting with the US FDA and subject to MAVERIC outcomes, Cardiol believes the results from MAVERIC will support a New Drug Application.
Data from Cardiol's Phase II MAvERIC-Pilot study presented at the American Heart Association Scientific Sessions 2024 showed that pericarditis patients treated with CardiolRx&#x2122; experienced marked and rapid reductions in pericarditis pain and inflammation, and a substantial reduction in the number of pericarditis recurrences per year.
Recurrent pericarditis is a debilitating heart condition that results in chest pain, shortness of breath and fatigue, physical limitations, reduced quality of life, and hospitalizations.
CardiolRx&#x2122;, which has been granted US FDA Orphan Drug Designation for this indication, is a small molecule oral drug targeting inflammasome pathway activation that is central to the development and progression of pericarditis.
Toronto, Ontario--(Newsfile Corp. - April 16, 2025) - Cardiol Therapeutics Inc. (NASDAQ:<a href="https://www.benzinga.com/stock/CRDL#NASDAQ">CRDL</a>) (TSX:<a href="https://www.benzinga.com/stock/CRDL#TSX">CRDL</a>) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, announced today that Northwestern University has enrolled the first patient in the pivotal Phase III MAVERIC trial ("MAVERIC") evaluating Cardiol's lead drug candidate CardiolRx&#x2122; for the prevention of recurrent pericarditis. This multi-center, randomized, double-blind, placebo-controlled trial is designed to definitively assess the impact of CardiolRx&#x2122; on preventing recurrent pericarditis in patients at high risk for disease relapse and to support regulatory approval.
MAVERIC is currently being initiated at pre-eminent cardiovascular clinical research sites throughout the United States under an Investigational New Drug application authorized by the United States Food and Drug Administration ("US FDA").&nbsp;
MAVERIC is a Phase III, multi-center, randomized, double-blind, placebo-controlled trial designed to enroll 110 patients with recurrent pericarditis at approximately 20 clinical sites across the United States, Canada, and Europe. Patients who have been treated with an interleukin-1 ("IL-1") blocker for at least 12 months and are scheduled to have this treatment discontinued, will be randomly assigned to receive either CardiolRx&#x2122; or placebo following cessation of the IL-1 blocker. Discontinuation of IL-1 blocker therapy is associated with a high risk for recurrence and has been reported to occur within 12 weeks in up to 75% of patients. The primary clinical objective of the trial will be to assess the impact of CardiolRx&#x2122; versus placebo on freedom from a new episode of recurrent pericarditis at 24 weeks. Other clinical endpoints include time to a new episode of pericarditis recurrence, and changes in patient-reported pericarditis chest pain score and changes to the inflammatory marker C-reactive protein.
MAVERIC, formerly referred to as MAVERIC-2, follows positive results from Cardiol's Phase II MAvERIC-Pilot study. Data from MAvERIC-Pilot were previously reported on November 18 at the American Heart Association Scientific Sessions 2024 and showed that patients experienced marked and rapid reductions in both pericarditis pain and inflammation that were maintained throughout the study. In addition, the results demonstrated a substantial reduction in pericarditis episodes per year. Treatment with CardiolRx&#x2122; was shown to be safe and well tolerated in a patient population who presented with a high degree of disease burden.

CRDL

Cardiol Therapeutics Enrolls First Patient In Pivotal Phase III MAVERIC Trial Evaluating CardiolRx For Prevention Of Recurrent Pericarditis

Abbott Expects Q2 2025 Adjusted EPS Of $1.23 to $1.27 Versus Consensus Of $1.25

Jefferies analyst Corey Tarlowe upgrades Grocery Outlet Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GO#NASDAQ">GO</a>) from Hold to Buy and raises the price target from $13 to $18.

Upgrades

Jefferies Upgrades Grocery Outlet Holding to Buy, Raises Price Target to $18

Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>) reported quarterly earnings of $1.09 per share which beat the analyst consensus estimate of $1.07 by 1.87 percent. This is a 11.22 percent increase over earnings of $0.98 per share from the same period last year. The company reported quarterly sales of $10.36 billion which missed the analyst consensus estimate of $10.40 billion by 0.39 percent. This is a 3.95 percent increase over sales of $9.96 billion the same period last year.

Abbott Laboratories Q1 2025 Adj EPS $1.09 Beats $1.07 Estimate, Sales $10.36B Miss $10.40B Estimate

HC Wainwright &amp; Co. analyst Mitchell Kapoor reiterates Sarepta Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) with a Neutral and maintains $75 price target.

SRPT

HC Wainwright & Co. Reiterates Neutral on Sarepta Therapeutics, Maintains $75 Price Target

Legal

Press Releases

ROSEN, LEADING INVESTOR COUNSEL, Encourages e.l.f. Beauty, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – ELF

Short Sellers

E.L.F. BEAUTY SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuits Against e.l.f. Beauty, Inc. - ELF

ELF Investors Have Opportunity to Lead e.l.f. Beauty, Inc. Securities Fraud Lawsuit

ELF Investors Have the Opportunity to Lead the e.l.f. Beauty Securities Fraud Lawsuit with Faruqi & Faruqi, LLP

Deadline Alert: e.l.f. Beauty, Inc. (ELF) Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit

INVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against e.l.f. Beauty, Inc. and Certain Officers - ELF

ROSEN, GLOBAL INVESTOR COUNSEL, Encourages e.l.f. Beauty, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – ELF

ELF LAWSUIT ALERT: The Gross Law Firm Notifies e.l.f. Beauty, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against AppLovin, Maravai, e.l.f. Beauty, and Manhattan Associates and Encourages Investors to Contact the Firm

MANH

MRVI

AXIL Brands

BellRing Brands

Coty

Big Tree Cloud Holdings Limited - Ordinary Shares

Big Tree Cloud Holdings

Estee Lauder Companies, Inc. (The) Common Stock

Estee Lauder Cos

Edgewell Personal Care Company Common Stock

Edgewell Personal Care

FitLife Brands

Herbalife

Honest Co

Interparfums

Kenvue

Lifevantage

Medifast

Nature's Sunshine Products, Inc. - Common Stock

Natures Sunshine Products

Natural Health Trends Corp. - Commn Stock

Natural Health Trends

Nu Skin Enterprises

Olaplex Hldgs

Paranovus Entertainment Technology Ltd. - Class A Ordinary Shares

Paranovus Entertainment

Safety Shot

The Beauty Health Company - Class A Common Stock

Beauty Health

United-Guardian

Unilever

Usana Health Sciences

Waldencast

Yatsen Holding Limited American Depositary Shares, each representing twenty (20) Class A Ordinary Shares

Yatsen Holding

JP Morgan

Piper Sandler

DA Davidson

Goldman Sachs

Canaccord Genuity

過去1週間でこれらの10つの大型株は最も悪いパフォーマンスを発揮しました。それで、あなたのポートフォリオに含まれていますか？
<ol>
<li>GameStop Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GME#NYSE">GME</a>) は、Keith Gill氏（通称<a class="ticker" href="https://www.benzinga.com//node/39237023">Roaring Kitty</a>氏）の復帰後、株価が29.59％下落したことにより、株価が下がりました。</li>
<li>Vistra Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VST#NYSE">VST</a>) の株価は14.78％下がっています。</li>
<li>酷い<a href="https://www.benzinga.com//node/39202678" target="_blank" rel="noreferrer noopener">第1四半期の収益</a>を受けて、NIO Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NIO#NYSE">NIO</a>) の株式は12.82％下落しました。</li>
<li>米国<a class="ticker" href="https://www.benzinga.com/stock/BBWI#NYSE">BBWI</a>（NYSE）は<a href="https://www.benzinga.com//node/39160023" target="_blank" rel="noreferrer noopener">同社の第1四半期の収益を発表してから</a>、株価が12％急落しました。</li>
<li>VinFast Auto Ltd。（NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VFS#NASDAQ">VFS</a>）の株価は11.92％低下しました。</li>
<li>Vertiv Holdings, LLC（NYSE:VRT）の株は9.70％下落しました。</li>
<li>Builders FirstSource, Inc.（NYSE:BLDR）の株式は先週9.42％下落しました。</li>
<li>E.L.F. Beauty, Inc. （NYSE:ELF）の株価も8.82％下がっています。</li>
<li>NICE Ltd（NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NICE#NASDAQ">NICE</a>）は先週、<a href="https://www.benzinga.com//node/38866576">第1四半期の業績発表</a>を受けて、8.29％下落しました。</li>
<li>Comfort Systems USA, Inc.（NYSE:FIX）の株式は先週8.12％下落しました。</li>
<li>Dell Technologies Inc（NYSE:DELL）は、先週に続いて7.53％下落し、<a href="https://www.benzinga.com//node/39108319">第1四半期の収益</a>が発表されました。</li>
</ol>

Comments

e.l.f. Beauty

ニュース

最新ニュース e.l.f. Beauty (NYSE:ELF) 株価情報

月曜日, 6 10, 2024

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル